We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
From May 2023 to May 2024
By Sabela Ojea
Seagen said Tuesday its shareholders voted in favor of Pfizer buying the company for $43 billion.
The biotechnology cancer specialist continues to expect to close the deal in late 2023 or early 2024 amid pending regulatory approvals.
In March, Pfizer said it entered into a definitive merger agreement with Seagen for $299 per share in cash to invest in cancer treatments.
The boards of directors of both parties back the transaction.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 30, 2023 16:00 ET (20:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
